STS injections for calcinosis in scleroderma
Treatments studied
Part of Bones, joints & muscles, Brain & nervous system, Hormones & metabolism, Skin clinical trials.
This trial tests if injecting a medication called STS directly into calcium deposits can relieve pain and symptoms. It may help patients with scleroderma or related conditions who have painful calcium lumps.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a diagnosis of systemic sclerosis, mixed connective tissue disease, or inflammatory myopathy.
- You are 18 years or older.
- You can understand and agree to the study procedures.
- You have calcium deposits shown on an X-ray or ultrasound.
- You need relief from symptoms caused by calcium deposits.
- You are not pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study will use CT scans to measure calcium deposits under the skin in people with scleroderma. It may help doctors better understand and track this condition.
This pilot study tests a medicine called sodium thiosulfate (given as a skin shot) to treat abnormal calcium or bone formation in places they don’t belong. It’s meant for people whose condition is causing significant problems, and who are not planning surgery for the next year.
This study looks at how a new drug affects skin scarring (fibrosis) in people with systemic sclerosis (SSc), a rare autoimmune disease. It aims to understand if this drug can help reduce the skin thickening and immune changes caused by SSc.
This trial tests whether stem cells from umbilical cord blood can help treat systemic sclerosis (scleroderma). The goal is to see if this treatment can improve skin thickening and overall symptoms for people who haven't had success with standard therapies.
This trial tests an experimental tablet called TollB-001 to see if it can help people with a type of systemic sclerosis that affects the skin and internal organs. It may reduce symptoms and slow the disease.
This study tests an experimental cell therapy (UTAA91) for people with hard-to-treat scleroderma. The goal is to see if this treatment can help when other options haven't worked.
Hear when a new Systemic Sclerosis (SSc) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.